VISTIN PHARMA ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.2 NOK | -0.89% |
|
+0.91% | -4.72% |
| May. 23 | Vistin Pharma ASA Approves Ordinary Dividend | CI |
| Apr. 24 | Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 305M 29.03M | Sales 2023 | 438M 41.74M | Capitalization | 1.03B 98.39M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -381K | Net income 2023 | 45M 4.29M | EV / Sales 2022 | 2.45 x |
| Net Debt 2022 | 47.73M 4.55M | Net cash position 2023 | 22.91M 2.18M | EV / Sales 2023 | 2.3 x |
| P/E ratio 2022 |
-144
x | P/E ratio 2023 |
22.7
x | Employees | 75 |
| Yield 2022 |
4.75% | Yield 2023 |
4.29% | Free-Float | 45.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vistin Pharma ASA
| 1 day | -0.89% | ||
| 1 week | +0.91% | ||
| Current month | -5.53% | ||
| 1 month | -4.72% | ||
| 3 months | -2.63% | ||
| 6 months | +2.78% | ||
| Current year | -4.72% |
1 week
21.80
23.00
1 month
21.5024.90
Current year
21.5024.90
1 year
20.6025.10
3 years
11.2525.35
5 years
5.0029.45
10 years
5.0029.45
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 20-02-29 | |
| Director of Finance/CFO | - | 20-03-01 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 20-05-31 | |
| Director/Board Member | 62 | 15-03-05 | |
| Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 22.2 | -0.89% | 1 387 |
| 24-05-24 | 22.4 | 0.00% | 3,636 |
| 24-05-23 | 22.4 | +1.82% | 348 |
| 24-05-22 | 22 | 0.00% | 35,965 |
Real-time Oslo Bors, May 27, 2024 at 10:45 am EDT
More quotes
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Companyâs customers are pharmaceutical companies worldwide.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -4.72% | 93.97M | |
| +16.40% | 42.95B | |
| +16.32% | 21.38B | |
| +20.14% | 15.05B | |
| +18.64% | 14.45B | |
| +53.58% | 13.04B | |
| -0.05% | 6.79B | |
| -12.64% | 6.72B | |
| -8.87% | 5.73B | |
| +11.21% | 5.47B |
- Stock Market
- Equities
- VISTN Stock
